MAPT and Alzheimer disease: Below we summarize recent work highlighting the role of cis P-tau as an early, pathogenic conformer in AD, TBI, VCID, and PE, as well as the therapeutic potential of the monoclonal antibody targeting cis P-tau (cis mAb).